Relationship Between Donor Source, Pre-Transplant Measurable Residual Disease, and Outcome After Allografting for Adults with Acute Myeloid Leukemia

Investigators retrospectively analyzed 1265 myelodysplastic neoplasm/AML and AML patients allografted in first or second remission with an HLA-matched sibling or unrelated donor, HLA-mismatched unrelated donor, an HLA-haploidentical donor, or umbilical cord blood at a single institution.